Biotech RadarJobs updated

COMPANY

Aptevo Therapeutics

HQ: Seattle, WA source · aptevotherapeutics.com ↗ · West Coast

Clinical Phase 2

Aptevo Therapeutics | A clinical-stage biotechnology company focused on developing bispecific immunotherapies for the treatment of cancer. From company website Source · Oct 12, 2026

Keywords: bispecific Chronic Lymphocytic Leukemia Acute Myeloid Leukemia AML Peripheral T-cell Lymphoma Psoriasis Ulcerative Colitis Prostate Cancer Non-Hodgkin's Lymphoma B-cell Small Lymphocytic Lymphoma Recurrent APVO436 ALG.APV-527 APVO210 ES414 TRU-016 (anti-CD37 protein therapeutic) TRU-016

Location: Seattle, WA · source · Oct 15, 2026

Profile checked Oct 10, 2026

$2.0MRaised (2 yrs)9Trials (company is sponsor)

Funding and NIH signals

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

  1. Raise Private placement: amount not published, announced May 27, 2026. Source: SEC filing. source ↗
  2. Raise Follow-on offering — Registered direct: $2M (total, as published), announced Apr 21, 2025. Source: SEC filing. source ↗
  3. Trial start Phase 1: Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML source ↗
  4. Trial start 1: APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML source ↗
  5. Trial start Phase 1/Phase 2: ALG.APV-527 First-in-human Study source ↗
  6. Trial start Phase 1: Study to Evaluate APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative Colitis source ↗
  7. Trial start Phase 1: Study of ES414 in Metastatic Castration-Resistant Prostate Cancer source ↗
  8. Trial start 1: Phase 1b Safety and Efficacy Study of TRU-016 source ↗
  9. Trial start Phase 1: A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma source ↗
  10. Trial start Phase 1/Phase 2: Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia source ↗
  11. Trial start 1: Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $2.0M. Last 2 years.

Clinical trials (lead sponsor) 9

RecordTitlePhaseStatusStartPrimary completion
NCT06634394APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML1RecruitingOct 1, 20242027-10 (estimated)
NCT05934539ALG.APV-527 First-in-human StudyPhase 1/Phase 2Unknown status (ClinicalTrials.gov)Dec 23, 2022Jan 1, 2024 (estimated)
NCT04973618Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AMLPhase 1Withdrawn2025-012026-01 (estimated)
NCT01188681Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic LeukemiaPhase 1/Phase 2Completed2010-092014-12 (actual)
NCT01644253Phase 1b Safety and Efficacy Study of TRU-0161Terminated2012-09Feb 24, 2020 (actual)
NCT03768219Study to Evaluate APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative ColitisPhase 1TerminatedMar 18, 2019Jun 30, 2020 (actual)
NCT02262910Study of ES414 in Metastatic Castration-Resistant Prostate CancerPhase 1Completed2015-012018-12 (actual)
NCT00614042Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma1Completed2008-012011-12 (actual)
NCT01317901A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent LymphomaPhase 1Completed2011-052013-04 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback